Remind Adolescents and Young Adults; REMIND-AYA
Phase 3
- Conditions
- HIV/AIDS
- Registration Number
- PACTR202303867267716
- Lead Sponsor
- Kilimanjaro Clinical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Participants must be on first line ART regimen (Tenofovir/Lamuvidine/Dolutegravir) or (Tenofovir/Lamuvidine/Efavirenz)
Participants must have had full disclosure of their HIV status
Participants must be able to read and understand Chichewa or English
Participants must be competent in the use of mobile devices.
Exclusion Criteria
Hospitalisation at the time of study entry
Prior participation in digital adherence health research
Enrolment in other HIV-related studies
Treatment for a comorbidity that significantly increases the participants’ pill burden.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method